Skip to Content

Norethindrone Pregnancy and Breastfeeding Warnings

Norethindrone is also known as: Aygestin, Camila, Deblitane, Errin, Heather, Incassia, Jencycla, Jolivette, Lyza, Nor-QD, Nora-Be, Norlyda, Norlyroc, Ortho Micronor, Sharobel

Medically reviewed on December 15, 2017.

Norethindrone Pregnancy Warnings

Animal reproduction studies have not been conducted with this drug. There are no controlled data from human pregnancy studies. Use during the first trimester of pregnancy may be associated with congenital malformations in male and female fetuses and virilization of the external genitalia of the female fetus.

AU TGA pregnancy category D: Drugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details.

US FDA pregnancy category X: Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.

Use is contraindicated.

AU TGA pregnancy category: D
US FDA pregnancy category: X

Comments:
-If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.
-Women of childbearing potential should be advised to avoid becoming pregnant while receiving this medication.

See references

Norethindrone Breastfeeding Warnings

This drug may slow neonatal bilirubin degradation; withholding of breastfeeding should be considered in neonates with severe/persistent jaundice requiring medical treatment.

Caution is recommended.
-According to some authorities: Use is contraindicated.

Excreted into human milk: Yes

Comments:
-The effects in the nursing infant are unknown.
-The WHO states that use is compatible with breastfeeding from 6 weeks postpartum.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "Australian Product Information." O 0
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. "Product Information. Micronor (norethindrone)" Ortho McNeil Pharmaceutical, Raritan, NJ.
  4. "Product Information. Aygestin (norethindrone)" Lederle Laboratories, Philadelphia, PA.
  5. "Product Information. Nor-QD (norethindrone)" Watson Laboratories Inc, Corona, CA.

References for breastfeeding information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. "Product Information. Micronor (norethindrone)" Ortho McNeil Pharmaceutical, Raritan, NJ.
  4. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT." ([cited 2013 -]):
  5. "Product Information. Aygestin (norethindrone)" Lederle Laboratories, Philadelphia, PA.
  6. "Product Information. Nor-QD (norethindrone)" Watson Laboratories Inc, Corona, CA.
  7. Department of Adolescent and Child Health and Development. UNICEF. World Health Organization "Breastfeeding and maternal medication: recommendations for drugs in the eleventh Who model list of essential drugs. Available from: URL: http://whqlibdoc.who.int/hq/2002/55732.pdf?ua=1" ([2003]):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide